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Abstract
Background: Benzodiazepines are commonly prescribed in residential aged care facilities (RACFs) for their sedative
and anxiolytic effects. The objective of this study was to investigate the association between benzodiazepine use
and sleep quality in residents of RACFs.
Methods: A cross-sectional study involving 383 participants was conducted in six Australian RACFs. Night-time
sleep quality, day-time drowsiness and day-time napping behavior were assessed using a validated questionnaire.
Logistic regression was used to compute adjusted odds ratios (AORs) and 95% confidence intervals (CIs) for the
association between benzodiazepine use and sleep quality. Covariates included pain, dementia severity, depression,
insomnia and other sedative use.
Results: Of the 383 residents (mean age 87.5 years, 77.5% female), 96(25.1%) used a benzodiazepine on a regular
basis. Residents who used long-acting benzodiazepines on a regular basis had higher night-time sleep quality than
non-users (AOR = 4.00, 95%CI 1.06 – 15.15). Residents who used short-acting benzodiazepines on a PRN only basis
had longer daytime napping times than non-users (AOR = 1.77, 95%CI 1.01 – 3.08). No benzodiazepine category
was associated with day-time drowsiness.
Conclusions: The association between benzodiazepine use and sleep quality is dependent on the half-life and
prescribing pattern of the benzodiazepine. Short-acting PRN benzodiazepines were associated with lower night
time sleep quality and longer day-time napping compared to long-acting regular benzodiazepines. Longitudinal
studies are needed to determine whether these findings reflect channeling of short-acting agents to residents at
higher risk of sleep disorders.
Keywords: Sleep, Sleep disorders, Sleep quality, Benzodiazepines, Hypnotics and sedatives, Homes for the aged,
Nursing homes
Background
Ageing is associated with a decrease in sleep length and
quality [1]. This is largely attributed to altered circadian
rhythms, lowered melatonin levels and increasing rates
of medical co-morbidities. Sleep disturbances manifest
as decreased total nocturnal sleep time, delayed sleep
onset, advanced circadian phase, reduced rapid-eye-
movement (REM) sleep and day-time napping and som-
nolence [2]. Sleep disorders predispose individuals to
hypertension, depression, cardiovascular and cerebrovas-
cular disease which further diminish quality of life [3].
In the short term, individuals experience impaired cogni-
tion and poor day-to-day functioning. Studies estimate
that 50% of individuals over 60 years of age suffer from
insomnia, with a higher prevalence amongst women [4].
Residents of RACFs experience a higher prevalence of
sleep disorders. This is likely attributable to environmental
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variables: noise, lighting, temperature and nursing times.
It is also attributable to resident characteristics [5]. More
than half of residents residing in Australian RACFs have a
diagnosis of dementia [6]. People with dementia have
higher rates and increased severity of sleep disorders with
sleep disturbance present in up to 71% of people with de-
mentia compared to 55.7% of people without dementia
[7]. Pain is associated with sleep disorders and is also
highly prevalent among residents [8].
The management of sleep problems in residents of
RACFs is often multifaceted. Non-pharmacological therap-
ies may include exercise, bright light exposure, nighttime
continence care, and cognitive behavioral interventions [9].
However, the results of these interventions are often incon-
sistent or provide modest benefits on selected aspects of
sleep quality. The most common treatment for sleep prob-
lems is pharmacological. Benzodiazepines, which enhance
the inhibitory effect of gamma-aminobutyric acid (GABA),
are commonly prescribed for their sedative and anxiolytic
properties [3]. Their sleep-promoting effects make them
among the most prevalent medication class among older
people [10]. Studies have reported the prevalence of regular
benzodiazepine use in Australian RACFs ranging from 12
to 42% [11].
Benzodiazepines are associated with modest improve-
ments to sleep latency and longer sleep duration; how-
ever, they suppress deep sleep which compromises
sleep’s restorative effects [12]. A meta-analysis by Glass
et al. found that the benefits associated with sedative use
are marginal and are outweighed by the risk of adverse
events. This is particularly clinically relevant for patients
at a high risk for falls or cognitive impairment [13].
Older people have increased sensitivity to adverse events,
despite growing tolerance to the sedative effects [12].
Adverse events include daytime drowsiness, lethargy, fa-
tigue, agitation, memory loss, impaired coordination and
falls [14]. Benzodiazepines may also contribute to cogni-
tive decline in people with dementia [15].
A recent Cochrane review revealed a paucity of appropri-
ately conducted studies that have investigated the benefits
and risks of benzodiazepines in people with dementia [16].
As low sleep quality is associated with impaired quality of
life [17], it is important to study the effects of benzodiazep-
ine use in vulnerable populations such as people with de-
mentia and those living in RACFs.
The objective of this study was to investigate the asso-




Data were drawn from a cross-sectional study of per-
manent residents in six low-level and high-level RACFs
in metropolitan Adelaide (population 1.2 million) and
regional Mt Gambier (population 25,000), South Australia.
In Australia, RACFs predominantly provide support and
service to older individuals unable to live independently at
home due to frailty, disability or illness. RACFs were clas-
sified according to level of support: ranging from aided
daily tasks and personal care in low-level RACFs to 24-h
nursing in high-level RACFs. The full study protocol has
been described previously [18].
Sample
Permanent residents aged 65 years or older were invited
to participate in the study. Inclusion criteria were ability
to participate in structured assessments in English.
Residents deemed medically unstable (e.g. delirium) or
estimated to have less than three months to live by facil-
ity staff were excluded from participation.
Of the 664 eligible residents in six RACFs, 603 were
invited to participate. Of the 603 residents invited to
participate, 220 were excluded (106 declined; 34 were
unwell, hospitalized or palliative; 54 had a third party
who could not be contacted or did not provide consent;
and 26 were excluded for other reasons). The final sam-
ple comprised 383 residents. Participants were similar to
all residents of the RACFs in terms of age (87.5 years
[SD 6.2] vs. 87.3 years [SD 6.4], p = 0.66), sex (77.5% fe-
male vs. 78.5% female, p = 0.90) and dementia diagnosis
(44.1% vs. 46.8%, p = 0.72).
Data source
All data were collected by three experienced study
nurses who underwent centralized training in the stand-
ard administration of the study assessment tools. Data
collection took place between April and August 2014.
Demographic, diagnostic and medication data were ex-
tracted from each resident’s electronic medical record
and medication chart. A standard data extraction form,
comprising a series of validated and widely used data
collection scales, enabled collection of other clinical
data. Both resident self-report and observational scales
completed by staff informants were utilized [18]. Where
possible, residents chose the most appropriate response
through verbal or written communication. If residents
were unable, a staff informant with at least two weeks fa-
miliarity with the specified resident completed the scale.
Medication assessment
Data on all charted medications were extracted from
each resident’s medication chart. Regular and as-needed
(PRN) prescription, non-prescription and complemen-
tary and alternative medications were considered. Regu-
lar use was defined as a documented regular sequence of
administration in the resident’s chart.
Medications were coded according to the Anatomical
Therapeutic Chemical (ATC) classification system, as
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recommended by the World Health Organization. Ben-
zodiazepines were defined as anxiolytic benzodiazepine
derivatives (N05BA), hypnotic and sedative benzodiazep-
ine derivatives (N05CD) or benzodiazepine related drugs
(N05CF). A resident was considered a benzodiazepine
user if he or she was charted a benzodiazepine on a
regular or PRN basis. Benzodiazepines were classified
according to half-life into two categories: short-acting
(half-life ≤24 h) and long-acting (half-life >24 h). Tem-
azepam, oxazepam, alprazolam, bromazepam, triazolam,
midazolam, lorazepam, zopiclone and zolpidem were classi-
fied as short-acting benzodiazepines. Diazepam, clobazam,
nitrazepam, flunitrazepam were classified as long-acting
benzodiazepines. Non-benzodiazepine sedative drugs in-
cluded other sedatives and hypnotics (e.g. melatonin, anti-
histamines) and medications with prominent sedative side
effects (e.g. antipsychotics, antidepressants, antiepileptics,
opioid analgesics).
Sleep quality
The primary outcome measure was sleep quality assessed
using a previously validated six-item questionnaire [19].
The questionnaire comprised three domains: night-time
sleep quality (overall self-reported sleep quality, sleeping
duration, restfulness), day-time drowsiness and day-time
napping behavior (frequency and duration) (Table 2). The
six-item questionnaire has been used previously among
older people living in self- and assisted-care villages to as-
sess the association between sleep quality and falls [20].
The scoring of the individual sleep domains within the
questionnaire was adapted from the method described
by St George et al [20]. The night-time sleep quality
score was derived from an aggregate of the three night-
time sleep items, with equal weighting for each domain.
This yielded a night-time sleep quality score ranging
between 3 and 15. Higher night-time sleep quality was
operationally defined as a score of 3–10 and lower sleep
quality as a score of 11–15, based on median score. Day-
time drowsiness was dichotomized as drowsy or non-
drowsy. Average number of hours napping per week was
calculated from the questions pertaining to napping
frequency and duration. Residents were categorized as
napping <3.5 h per week (less than half an hour per day),
or ≥3.5 h per week [20].
Covariates
Co-morbidities were extracted from resident electronic
medical records and included depression, insomnia and
history of falls. The Charlson Comorbidity Index (CCI)
was calculated for each resident [21]. Dementia severity
was measured in residents with and without a dementia
diagnosis with the Dementia Severity Rating Scale [22].
Resident agitation and aggression was assessed using the
Neuropsychiatric Inventory Nursing Home version (NPI-
NH) [23]. Activities of daily living were assessed with the
Katz Activities of Daily Living (ADL) index [24]. Pain was
observed and assessed using the Pain Assessment in
Advanced Dementia (PAINAD) Scale [25].
Statistical analysis
Descriptive analyses were conducted using Pearson Chi-
square tests for categorical variables, Student’s t-tests for
continuous variables and Mann-Whitney U tests for ordinal
variables. Odds ratios (ORs) and 95% confidence intervals
(CIs) of the associations between different benzodiazepine
categories and sleep domains were computed with binary
logistic regression analyses. Analyses were adjusted for age,
sex, dementia severity rating scale, any pain reported on
the PAINAD scale, depression, insomnia and non-
benzodiazepine sedative use. These factors were used to ad-
just the analyses because they were deemed clinically rele-
vant based on previous research [2]. Sensitivity analysis was
performed by initially removing insomnia diagnosis to as-
sess for potential over-correction, and this did not affect
the results. Benzodiazepine use was analyzed separately
based on half-life classification (short or long-acting) and
type of prescription (regular or PRN). Separate models were
run for the association between each benzodiazepine cat-
egory and each different sleep quality domain i.e. night-
time sleep quality, day-time drowsiness and day-time nap-
ping behavior. The reference groups were those residents
not taking these drugs.
Missing values were imputed with multiple imputation
with five iterations. This was because multiple imput-
ation is superior to complete case analyses when data
are missing at random [26]. Values were imputed for
sleep quality questionnaire (24.8% missing) and PAINAD
(1.0% missing). Analyses were undertaken using the Stat-
istical Package for the Social Sciences (SPSS, version
21.0, Chicago, IL, USA).
Ethical considerations
The study was approved by the Royal Australian College
of General Practitioners (RACGP) National Research and
Evaluation Ethics Committee and the Monash University
Human Research Ethics Committee. All participants were
informed about the study verbally and in writing. Written
informed consent was obtained from the residents, or
their guardian, next of kin, or significant other if unable.
All study procedures were conducted in accordance with
the Australian National Statement for Ethical Conduct in
Human Research.
Results
Of the residents, 229 (59.8%) were able to self-complete
the sleep questionnaire, with the remainder completed
by a staff informant or carer. Demographic characteris-
tics of residents in RACFs with lower and higher night-
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time sleep quality were similar (Table 1). The mean age
of residents was 87.5 years (SD = 6.19). Of the 383
participants, 297 (77.5%) were female and 135 (35.2%)
lived in high-level RACFs. In total, 169 (44.1%) had a de-
mentia diagnosis and 230 (60.1%) had a depression diag-
nosis. Residents with lower night-time sleep quality were
more likely to exhibit pain (34.6% vs 25.0%, p = 0.04)
compared to those with higher night-time sleep quality
(Table 1).
Overall, 96 (25.1%) residents were charted regular ben-
zodiazepines and 121 (31.6%) were charted PRN benzodi-
azepines. Eighty residents (20.9%) used benzodiazepines
on a PRN only basis, with the majority being short-acting
formulations (n = 69). Forty-one (10.7%) residents used
more than one category of benzodiazepine.
Residents who used benzodiazepines had a higher preva-
lence of diagnosed insomnia (21.3% vs 4.9%, p < 0.01),
anxiety (44.9% vs 32.2%, p = 0.01) and depression (68.0% vs
53.2%, p < 0.01) than residents who did not use benz-
odiazepines. Residents taking benzodiazepines had higher
prevalence of agitation or aggression compared to those resi-
dents not taking benzodiazepines (34.3% vs 19.5%, p < 0.01).
Resident responses to the six item sleep questionnaire are
shown in Table 2. There were no statistically significant dif-
ferences between users and non-users of benzodiazepines
in any of the sleep questionnaire items or domains.
Night-time sleep quality
Overall, 181 (47.3%) residents had lower night-time sleep
quality (score ≤10). In adjusted analyses, use of regular
long-acting benzodiazepines was significantly associated
with higher sleep quality (AOR = 4.00, 95%CI = 1.06 –
15.15) (Table 3). Use of PRN short-acting benzodiazepines
was associated with lower night-time sleep quality, how-
ever this did not reach statistical significance (AOR = 0.59,
95%CI = 0.34 – 1.02).
Day-time drowsiness
Of benzodiazepine users, 49.5% reported day-time drow-
siness compared to 55.3% of non-users. No statistically
significant associations were found in unadjusted and
adjusted analyses between use of any benzodiazepine
category and day-time drowsiness (Table 3).
Average weekly napping time
There was no significant difference in mean daytime
napping time between benzodiazepine users and non-
users overall (3.03 vs 3.01 h per week, p = 0.97) (Table 1).
However, the use of PRN only benzodiazepines was
found to be associated with increased day-time napping
time (AOR = 1.77, 95%CI = 1.01-3.08).
Table 1 Characteristics of residents with higher and lower sleep quality in Australian residential aged care facilities
All residents Higher sleep quality (NTSQS >10) Lower sleep quality (NTSQS ≤10) P value
383 202 53% 181 47%
Demographic characteristics
Age (mean ± SD) 87.53 (6.19) 87.62 (6.16) 87.43 (6.22) 0.77a
Female 297 160 79.2% 137 75.7% 0.39b
High Level Care 135 79 39.1% 56 30.9% 0.09b
Born in Australia 298 150 74.3% 148 81.8% 0.10b
Functional characteristics
Charlson’s comorbidity index (median, IQR) 2.00 (1.00, 3.00) 2.00 (1.00, 3.00) 2.00 (1.00, 4.00) 0.39c
ADLs (median, IQR) 1.00 (4.00, 6.00) 3.00 (1.00, 6.00) 4.00 (1.00, 6.00) 0.66c
DSRS (mean ± SD) 19.09 (16.87) 20.19 (16.57) 17.85 (17.10) 0.21a
PAINAD, any 113 50 24.8% 63 34.8% 0.04b
Medical diagnoses and medications
Dementia 169 94 46.5% 75 41.4% 0.35b
Insomnia 48 22 10.9% 26 14.4% 0.37b
Anxiety 146 78 38.6% 68 37.6% 0.81b
Depression 230 115 56.9% 115 63.5% 0.21b
Any non-benzodiazepine sedatives 272 145 71.8% 127 70.2% 0.71b
NTSQS night-time sleep quality score, ACAT aged care assessment team, ADLs activities of daily living, DSRS dementia severity rating scale, PAINAD Pain Assessment
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Table 2 Sleep quality in users and non-users of benzodiazepines in Australian residential aged care facilities. (Based on 6-item questionnaire
and derived sleep domain scores)
All residents (n = 383) Non-Benzodiazepine user (n = 204) Benzodiazepine user(n = 179) P
Q1: SLEEP QUALITY: Over the past month rate
the quality of your night time sleep?
Very poor 10 3 1.5% 7 3.9% 0.22a
Poor 44 19 9.3% 25 14.0%
Okay 96 56 27.5% 40 22.3%
Good 162 84 41.2% 78 43.6%
Very good 72 43 21.1% 29 16.2%
Q2: SLEEP DURATION: How much sleep
do you get each night?
< 4h 7 3 1.5% 4 2.2% 0.06a
4-6h 89 43 21.1% 46 25.7%
6-8h 180 93 45.6% 87 48.6%
6-10h 84 49 24.0% 35 19.6%
> 10h 22 15 7.4% 7 3.9%
Q3: RESTFUL SLEEP: How restless or
restful is your sleep as a rule?
Very restless 10 4 2.0% 6 3.4% 0.16a
Restless 62 30 14.7% 32 17.9%
Not very 60 29 14.2% 31 17.3%
Restful 191 107 52.5% 84 46.9%
Very restful 60 34 16.7% 26 14.5%
Q4: WAKING CONDITION: How clear
headed do you feel when you wake
in the morning?
Alert 184 104 51.0% 80 44.7% 0.58a
Slightly drowsy 151 71 34.8% 80 44.7%
Fairly drowsy 33 22 10.8% 11 6.1%
Very drowsy 15 8 3.9% 7 3.9%
Q5: NAPPING FREQUENCY: How regularly
do you sleep, nap, or lie down during
the day?
Nearly every day 171 87 42.6% 84 46.9% 0.47a
A few times a week 52 30 14.7% 22 12.3%
Once or twice a week 47 21 10.3% 26 14.5%
Once or twice a month 27 21 10.3% 6 3.4%
Never or hardly ever 86 45 22.1% 41 22.9%
Q6: NAPPING DURATION: In general how
much sleep would you say you get
on these days?
0.52a
None 73 39 19.1% 34 19.0%
Less than 1/2h 109 54 26.5% 55 30.7%
1/2 to 1h 129 70 34.3% 59 33.0%
1 to 2h 54 32 15.7% 22 12.3%
More than 2h 18 9 4.4% 9 5.0%
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Discussion
This was one of the first studies to investigate the associ-
ation between benzodiazepines and sleep quality in RACFs
[27, 28]. The primary finding was that PRN only short-
acting benzodiazepine use was associated with lower night-
time sleep quality while regular long-acting benzodiazepine
use was associated with higher night-time sleep quality.
The prevalence of benzodiazepine use amongst RACF
residents in our study was similar to previous Australian
and international studies [11, 29, 30]. The proportion of
residents classified as having lower night-time sleep
quality is similar to previous research that reports be-
tween 40-65% of older adults have some form of sleep
disturbance [31]. St George et al., using the same six-
item questionnaire, found a similar prevalence of lower
night-time sleep quality and an association between pain
and lower night-time sleep quality. Contrary to previous
studies, our study found no significant association be-
tween night-time sleep quality and age, sex and medical
diagnoses, in particular dementia severity and depression
[2, 4, 10]. Both age and dementia are known to adversely
impact on circadian rhythms, with increasing dementia
severity impacting further on sleep.
There was a statistically significant positive association
between regular long-acting benzodiazepine use and
higher night-time sleep quality. However, the sample size
for regular long-acting benzodiazepines (n = 14) was
modest in comparison to other categories. Traditionally,
long-acting benzodiazepines such as diazepam are more
commonly prescribed to manage anxiety disorders [32].
As such, residents using long-acting benzodiazepines
may not have had existing sleep problems.
In our study, there was an association between use of
short-acting benzodiazepines on a PRN basis only and lower
Table 2 Sleep quality in users and non-users of benzodiazepines in Australian residential aged care facilities. (Based on 6-item questionnaire
and derived sleep domain scores) (Continued)
SLEEP QUALITY DOMAINS
Night-time Sleep Quality Score (Category)
Higher 202 113 55.4% 89 49.7% 0.26a
Lower 181 91 44.4% 90 50.6%
Night-time Sleep Quality Score (Mean) 10.29 (2.45) 10.52 (2.37) 10.02 (2.52) 0.05b
Day-time Drowsiness (Category)
Alert 183 103 50.5% 80 44.7% 0.26c
Drowsy 200 101 49.5% 99 55.3%
Napping Score (Category)
< 3.5h/week 256 137 67.2% 119 66.5% 0.82a
≥ 3.5h/week 127 67 32.8% 60 33.5%




Table 3 Association between benzodiazepine use and sleep quality, day-time drowsiness and napping in Australian residential aged
care facilities
Association between BZD and higher
night-time sleep quality
Association between BZD and day-
time drowsiness
Association between BZD and longer average
napping time (≥3.5 h per week)
N AORa CI P AORa CI P AORa CI P
Any BZD 179 0.82 0.53 – 1.26 0.36 1.27 0.81 – 1.98 0.30 1.04 0.65 – 1.66 0.87
Any Regular
- short-acting 83 0.91 0.54 – 1.53 0.71 1.05 0.62 – 1.80 0.85 0.70 0.40 – 1.22 0.21
- long-acting 14 4.00 1.06 – 15.15 0.04 1.53 0.48 – 4.90 0.48 0.32 0.07 – 1.50 0.15
PRN only
- short-acting 69 0.59 0.34 – 1.02 0.06 1.29 0.73 – 2.26 0.38 1.77 1.01 – 3.08 0.04
- long-acting 11 0.77 0.22 – 2.67 0.68 1.29 0.37 – 4.46 0.69 1.18 0.30 – 4.70 0.81
AOR adjusted odds ratio, CI 95% confidence interval, BZD benzodiazepine
aeach model adjusted for age, sex, DSRS (Dementia Severity Rating Scale), PAINAD (Pain Assessment in Advanced Dementia Scale), depression, insomnia and use
of non-benzodiazepine sedatives
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night-time sleep quality, although this was not statistically
significant. The effects of benzodiazepine use on sleep qual-
ity have been mixed. For example, a systematic review of
randomized controlled trials found that sedative hypnotics
offer statistically significant, but small, improvements in
sleep quality [13]. However, long-term benzodiazepine use is
associated with tolerance which may negate the therapeutic
effects of benzodiazepines [27]. As our study was cross-
sectional we were not able to investigate tolerance and dur-
ation of benzodiazepine use. A cross-sectional study by
Béland et al. also reported an association between benzodi-
azepines and poor sleep quality, which the authors attrib-
uted to the physiological tolerance mechanism [33]. The use
of short-acting benzodiazepines, such as temazepam, is rec-
ommended as a first line short-term treatment for insomnia
by the Australian Therapeutics Guidelines [32]. Thus, this
finding may be attributed to the role of using short-acting
benzodiazepines, as required, in residents who are experien-
cing poor sleep quality. Individuals with poor sleep quality
may be more likely to be prescribed PRN short-acting ben-
zodiazepines, and this may highlight potential confounding
by indication.
There was an association between PRN benzodiazep-
ine only use and longer day-time napping. Australian
Therapeutic Guidelines recommend the use of PRN
medication in both the treatment of insomnia and anx-
iety [32]. Historically, short-acting benzodiazepines have
been attributed with lower rates of adverse events and
lowered risk of residual next-day sequelae such as nap-
ping [34]. Clinician awareness of preventing adverse
events is seen through prescribing habits and patterns.
Thus, our findings may reflect channeling of PRN medi-
cations to residents susceptible to daytime napping, par-
ticularly those with acute rather than chronic insomnia
[35]. This study found no association between benzodi-
azepine use and day-time drowsiness, whereas previous
research indicates benzodiazepine users are at a greater
risk of somnolence [10, 28]. The different effects of vary-
ing formulations and regimens of benzodiazepines on the
sleep domains highlights the need for informed decision
making when it comes to prescribing these medications.
Strengths and limitations
Demographic and diagnostic characteristics were similar
among participants and non-participants, thus the study
sample presented is likely representative of all residents in
the RACFs. Despite having a larger sample size than previous
research [27], generalizability of the study results may be
limited and findings may not be applicable to other demo-
graphics and settings. The cross-sectional study design lim-
ited our ability to infer causality between associated factors.
Strengths lie in our method of data collection. Diagnos-
tic data were extracted from each resident’s most recent
electronic medical records. Likewise, medication use was
extracted from current medication charts, providing a
more accurate reflection of actual medication exposure
than relying on prescribing or dispensing data to ascertain
medication use. We conducted separate analyses for regu-
lar and PRN benzodiazepine use and for short and long-
acting benzodiazepine use. However, we did not investi-
gate the possible impact of benzodiazepine dose and dur-
ation, which could have effects through tolerance with
long term use, or withdrawal worsening sleep quality in
residents with recent dose reduction or recent change
from long to short acting benzodiazepines. Consideration
was made for a range of clinically relevant covariates;
however, we did not adjust our analyses for sleep disorders
other than insomnia, such as obstructive sleep apnea and
restless leg syndrome [10]. Other potential factors previ-
ously studied, such as environment, poor sleep hygiene,
social connections and fitness levels, were not considered
[10, 20]. The majority of observational or self-reported
data in our study were gathered with widely-used, previ-
ously validated scales that have been demonstrated to be
appropriate for use in aged care facilities or people with
dementia. However, the results should be interpreted in
light of the fact that 40.2% of the sampled residents
needed assistance with completing the sleep question-
naire, and a proportion of data were imputed. Residents
needing assistance with the questionnaire were largely
cognitively impaired. Although a staff or carer proxy was
used in these cases, they had to be familiar with the resi-
dent and their sleep behavior (i.e. had cared for the resi-
dent for a minimum of two weeks). By including residents
with cognitive impairment, generalizability within the
aged care setting was maximized. The small number of
regular long-acting benzodiazepine users, and hence wide
confidence interval, means these results should be inter-
preted with caution.
Conclusions
The association between benzodiazepine use and sleep
quality in residents of aged care facilities is dependent on
the half-life and prescribing pattern of the benzodiazepine.
Short-acting PRN benzodiazepines were associated with
lower night time sleep quality and longer day-time nap-
ping compared to long-acting regular benzodiazepines.
Longitudinal studies are needed to determine whether
these findings reflect channeling of the short-acting agents
and PRN prescribing to residents at higher risk of sleep
disorders, or acute rather than chronic insomnia. Further
research should be undertaken to explore the effect of
benzodiazepine dose and duration on sleep quality.
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